5325232026-05-082026-05-085325232026-05-085325232026-05-08ChangeInManagementDomain15325232026-05-082026-05-08ChangeInManagementDomain15325232026-05-08ChangeInManagementDomain25325232026-05-082026-05-08ChangeInManagementDomain25325232026-05-08ChangeInManagementDomain35325232026-05-082026-05-08ChangeInManagementDomain35325232026-05-08ChangeInManagementDomain45325232026-05-082026-05-08ChangeInManagementDomain45325232026-05-08ChangeInManagementDomain55325232026-05-082026-05-08ChangeInManagementDomain55325232026-05-08ChangeInManagementDomain65325232026-05-082026-05-08ChangeInManagementDomain65325232026-05-08ChangeInManagementDomain75325232026-05-082026-05-08ChangeInManagementDomain75325232026-05-08ChangeInManagementDomain85325232026-05-082026-05-08ChangeInManagementDomain85325232026-05-08ChangeInManagementDomain95325232026-05-082026-05-08ChangeInManagementDomain95325232026-05-08ChangeInManagementDomain105325232026-05-082026-05-08ChangeInManagementDomain105325232026-05-08ChangeInManagementDomain115325232026-05-082026-05-08ChangeInManagementDomain11xbrli:pureBIOCONBiocon Limited532523NOTLISTEDINE376G01013trueListed Entity (self)true2026-05-0718:00:0020:45:00112026-05-08AppointmentDirectorNon - Executive Independent DirectorNot ApplicableNot ApplicableMr.Rajiv Malik2026-08-0124With a distinguished career spanning leadership roles in some of the world’s most respected pharmaceutical organisations, Rajiv brings deep expertise in global commercial, scientific, operational, and business development activities. He has served as President of Viatris and Mylan, played a pivotal role in integrating Mylan and Upjohn (formerly of Pfizer) to form Viatris, and contributed significantly as CEO of Matrix Laboratories Limited, Head of Global Development and Registrations for Sandoz GmbH, and Head of Global Regulatory Affairs and Pharma Research for Ranbaxy. Dr. Malik’s has extensive experience in public company management, finance, accounting and capital markets, global business, healthcare industry, information security, legal and regulatory oversight, risk oversight and compliance, and strategy and M&A acquired over his extensive career in the healthcare industry. Notably, at Mylan he was responsible for leading global commercial, scientific, operational, information technology and business development activities in more than 165 countries and territories, overseeing a portfolio of more than 7,500 products, a pipeline of approximately 1,200 products, and more than 40 manufacturing facilities around the world. He holds a Master’s degree in pharmaceutical technology from Panjab University, India.NonetruefalseAppointmentDirectorNon - Executive Independent DirectorNot ApplicableNot ApplicableMr.Daniel Bradbury2026-08-0124Daniel Bradbury is a highly accomplished life sciences executive with over 40 years of experience in shaping and executing transformative business strategies across the pharmaceutical and biotechnology sectors. As Executive Chairman, former CEO, and Co-Founder of Equillium Inc., he has helped advance therapies for severe autoimmune and inflammatory disorders. He serves as Managing Member at BioBrit LLC and holds numerous board positions, including Director at Vivani Medical, Inc., Board Chairman at Castle Biosciences Inc., Biolinq Inc., Sensulin LLC, Del Nova, Inc., Amplo Biotechnology, Persephone Biosciences. Mr. Bradbury is also a Member of the Board of Trustees of the Keck Graduate Institute and the Advisory Council at the Rady School of Management, San Diego, US. He was also the former CEO of Amylin Pharmaceuticals, a leading metabolic disease company, acquired by Bristol Myers Squibb in 2012. Daniel Bradbury’s visionary leadership is widely recognized, having received the Director of the Year Award from the Corporate Directors Forum for Lifetime Achievement in Corporate Governance (2023) and for Enhancing Economic Value (2012), as well as being an EY Entrepreneur of the Year Finalist in 2012. Mr. Bradbury’s educational background includes the International Executive Program at INSEAD, France; Diploma in Management Studies from the University of West London, UK; and a Bachelor of Pharmacy from Nottingham University, UK.NonetruefalseAppointmentDirectorNon - Executive Independent DirectorNot ApplicableNot ApplicableMr.Peter Baron Piot2026-08-0124Peter Baron Piot is a Belgian-British microbiologist born on 17 February 1949 in Keerbergen, Belgium. He is renowned for his pioneering research into infectious diseases, particularly Ebola and AIDS. Peter earned his MD from the University of Ghent and a PhD in Microbiology from the University of Antwerp. He further specialised in Tropical Medicine, Clinical Virology, Biostatistics and Epidemiology, and completed advanced research management training at Harvard, as well as serving as Senior Fellow in Infectious Diseases at the University of Washington. Peter played a crucial role in the discovery of the Ebola virus in 1976 and was instrumental in leading efforts to contain the first-ever recorded Ebola epidemic. Following this, he became a pioneering researcher in AIDS, contributing significantly to the understanding and management of the disease. Over the course of his career, Peter has held key positions in international organisations such as the United Nations and the World Health Organization, where he focused on AIDS research and management. His leadership has helped drive strategic initiatives and shape public health policies globally. Piot has served as a professor at several universities around the world. He is a prolific author, having written 16 books and published over 600 scientific articles, which reflect his dedication to advancing medical science and public health. Among his numerous honours, Peter Piot has received the World Health Organization Life Achievement Award (2023), Canada Gairdner Global Health Award (2015), Robert Koch Gold Medal (2015), Time Person of the Year as one of “The Ebola Fighters” (2014), Prince Mahidol Award for Public Health (2014), Hideyo Noguchi Africa Prize for Medical Research (2013), the Frank A. Calderone Prize in Public Health (2003), and the Nelson Mandela Award for Health and Human Rights (2001). These prestigious accolades underscore his exceptional contributions to global health and the advancement of medical science.NonetruefalseAppointmentDirectorNon - Executive Independent DirectorNot ApplicableNot ApplicableMr.Arun Suresh Chandravarkar2026-08-0124Dr. Arun Chandavarkar is an eminent figure in the biopharmaceutical sector, renowned for his visionary leadership and pioneering contributions to healthcare innovation. His professional journey spans over three decades at Biocon, where he has played a pivotal role in shaping the company’s strategy and operations, focused on expanding access to high-quality, affordable biopharmaceuticals and specialty medicines for chronic therapies worldwide. Under his leadership, Biocon has made significant investments in cutting-edge R&D and efficient, compliant operations that translated into a unique and differentiated product portfolio straddling fermentation-derived complex generics, biosimilars and novel biologics, all aimed at a worldwide patient population Dr. Chandavarkar’s leadership has resulted in substantial investments in cutting-edge research, yielding a differentiated product portfolio that addresses unmet medical needs across global patient populations. His industry impact extends beyond Biocon, as Chairperson of the National Committee on Biotechnology for the Confederation of Indian Industry (CII) in 2016-17, where he championed biotechnology advancement and regulatory excellence. His academic credentials are exceptional, holding a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Bombay, and a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology (MIT), Cambridge, U.S.NonetruefalseAppointmentDirectorNon - Executive Independent DirectorNot ApplicableNot ApplicableMs.Nivruti Rai2026-08-0124Nivruti Rai is a renowned leader in technology and investment, with a proven track record in driving strategic growth and transformation across the public and private sectors. As Managing Director & CEO of Invest India, the Government of India's national investment facilitation agency, she plays a pivotal role in fostering investment opportunities and shaping India’s economic landscape. Previously, she served as Country Head for Intel India (2016–2023). She also headed Intel’s Worldwide Automotive Foundry business, broadening the company’s global footprint in advanced semiconductor manufacturing and automotive solutions. Ms. Rai is recognized as an influential voice in technology and investment worldwide, having spoken at premier global gatherings such as the World Economic Forum (WEF) and the Reykjavik Global Forum, as well as at leading academic institutions including Tel Aviv University, Duke University, and New York University. Her exceptional contributions have earned her the prestigious Nari Shakti Puraskar (Woman Power Award), India’s highest civilian recognition for women, and she has been listed among Fortune India’s Most Powerful Women from 2018 to 2024. Her academic credentials are equally impressive, with a Global Board of Director Certification Program from Harvard Business School, an Executive MBA from Stanford Business School, a Master’s degree in Industrial Engineering from Oregon State University, and both an M.Sc. in Applied Mathematics and a B.Sc. in Statistics from the University of Lucknow, India.NonetruefalseAppointmentDirectorNon - Executive Non -Independent DirectorNot ApplicableNot ApplicableMr.Thomas Jason Roberts2026-08-010Dr. Thomas Jason Roberts is a distinguished Head and Neck Oncologist at the Massachusetts General Hospital Cancer Center, with extensive leadership experience as Clinical Director of Oncology Services at Massachusetts General Brigham Healthcare at Home. He also serves as an Instructor of Medicine at Harvard Medical School, contributing to the academic and clinical advancement of the field. Dr. Roberts holds an M.D. from Stanford University School of Medicine and an MBA from the Stanford Graduate School of Business, reflecting his strong foundation in both medical science and business management. His academic journey began with a B.A. with High Distinction from the University of Virginia in 2009. He has completed an Oncology Fellowship at Dana-Farber Cancer Institute/Massachusetts General Hospital and an Internal Medicine Residency at Massachusetts General Hospital, further solidifying his expertise in oncology and patient care.Mr. Thomas Jason Roberts is son-in-law of Prof. Ravi Rasendra Mazumdar and brother-in-law of Mr. Eric Vivek Mazumdar.truefalseAppointmentSenior Management PersonnelSenior Management PersonnelMr.Anuj Goel2026-05-07Dr. Anuj Goel is the Chief Development Officer (CDO) at Biocon, leading all Research & Development functions; R&D-CMC, Clinical Development & Medical Affairs and Regulatory Affairs. Anuj is a Biocon veteran, having joined the company in 1996 to start the process development group in R&D. He has had diverse experience working on solid state fermentation, deep tank enzyme production, fermentation of small molecules metabolites and recombinant proteins and peptides using bacterial, fungal and mammalian cell lines. He served as the CDO of Biocon Biologics between October 2024 and March 2026. Anuj has been instrumental in transforming Biocon’s development labs into premier facilities that drive R&D excellence, fostering innovation and growth. Over the years, his team has developed technology for statins, immunosuppressants, recombinant proteins, insulins and monoclonal antibodies. He brings extensive experience and comprehensive organizational leadership, having served as a bench scientist, project manager, portfolio leader, function head and has led the R&D-CMC department. Anuj has mentored many emerging leaders at Biocon Biologics, demonstrating his exceptional leadership skills. He has also been a key stakeholder in advancing the biosimilars portfolio over the years through collaborations with partners and stakeholders. Anuj holds a PhD in Biotechnology from Pune University and has more than 15 publications and patents to his credit.AppointmentSenior Management PersonnelSenior Management PersonnelMr.Susheel Umesh2026-05-07Susheel Umesh is the Chief Commercial Officer (CCO) – Emerging Markets, and Head of Global API and Head of Global Business Development at Biocon. Susheel Umesh is responsible for scaling up the company’s business in Emerging Markets, expanding its footprint, strengthening patient centric business initiatives in these markets, and leading the global API business. Susheel has over 35 years of experience in the pharmaceuticals and healthcare industries. He has excelled in several global leadership roles across Asia-Pacific, Africa and the European regions, leading large business units with some of the top global pharmaceutical brands. He served as the CCO – Emerging Markets at Biocon Biologics from March 2021 to March 2026. Before joining Biocon Biologics, Susheel led the domestic formulations business at Panacea Biotec as its Chief Executive Officer. He was also the Managing Director of Abbott’s Specialty Care business in India, where he built a portfolio across Diabetes, Cardiology, CNS, Dermatology, and hospital-based product ranges. Susheel held diverse leadership roles at Sanofi over 23 years. He headed multi country operations as Chairman of Sanofi Kenya Ltd. and served as Managing Director of Sanofi Eastern and Southern Africa, leading operations across 14 Sub Saharan African countries. As Global Insulin Marketing Head of Sanofi based in Paris, Susheel worked with multiple stakeholders and was responsible for developing a global launch strategy for a key insulin brand, aligning regulatory timelines and planning global clinical studies. He also headed Business Units, Business Development and Operational Excellence across varied generic products and scientific research-oriented brands. He has overseen diverse portfolios across therapeutic areas including Diabetes, Cardiology, Neuropsychiatry, Oncology, Vaccines, Transplantation, Dermatology, GI, Pain, Hospital, and Institutional Business. He holds an MBA in Marketing from Pune University and a Bachelor of Pharmacy from Bombay University.AppointmentAuditorsStatutory AuditorM/s.Batliboi & Associates2026-08-0660S.R. Batliboi & Associates LLP (“the Firm”), a limited liability partnership firm incorporated in India, in 1949 with its registered office in Kolkata and has offices across key cities in India. The firm is registered with the Institute of Chartered Accountants of India (“ICAI”) with (ICAI Firm Registration No. 101049W/E300004). The S. R. Batliboi & Affiliates network of firms includes – S. R. Batliboi & Co LLP, S. R. Batliboi & Associates LLP, S R B C & CO LLP, S. V. Ghatalia & Associates LLP. All the network firms including the Firm are primarily engaged in providing audit and assurance services to its clients. They along-with its network firms audit several large listed and private companies across diverse market segments including Industrial, Infrastructure, Consumer Products, Financial Services, Technology, Media and Entertainment, Telecommunications and Professional services.trueTenure completionAuditorsStatutory AuditorM/s.B S R & Co. LLP2026-08-06Re-appointmentDirectorNon - Executive Independent DirectorNot ApplicableNot ApplicableMs.Rekha Mehrotra Menon2026-08-0660false